Fatal Interaction between Clarithromycin and Colchicine in Patients with Renal Insufficiency: A Retrospective Study
Author(s) -
Ivan FanNgai Hung,
A. K. L. Wu,
Vincent ChiChung Cheng,
Bone S. F. Tang,
Kelvin KaiWang To,
ChungKwong Yeung,
Patrick C. Y. Woo,
Susanna K. P. Lau,
Bmy Cheung,
KwokYung Yuen
Publication year - 2005
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1086/431592
Subject(s) - medicine , clarithromycin , concomitant , retrospective cohort study , colchicine , gout , relative risk , gastroenterology , surgery , confidence interval , helicobacter pylori
Clarithromycin is frequently used to treat community-acquired pneumonia in elderly persons. Like erythromycin, it may interact with other drugs by interfering with metabolism by cytochrome P450 enzymes and with the P-glycoprotein transporter system. Colchicine, used for treatment of acute gout and for prophylaxis, may cause bone marrow toxicity. It is metabolized by CYP3A4 and is transported by P-glycoprotein. Initial case reports suggested potentially fatal interactions between clarithromycin and colchicine.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom